GRAIL Inc. (NASDAQ: GRAL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
72.70
+2.43+3.46%
Earnings
Up 3.5% — Reported earnings — EPS beat by 17%, revenue beat by 4%.
High confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -10.37 | Insider Own | 23.67% | Shs Outstand | 42.92M | Perf Week | 12.85% |
| Market Cap | 3.12B | Forward P/E | - | EPS next Y | -10.62 | Insider Trans | -3.07% | Shs Float | 39.29M | Perf Month | 5.44% |
| Enterprise Value | 2.34B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 19.68% | Perf Quarter | 30.61% |
| Income | -395.00M | P/S | 19.87 | EPS this Y | 0.34% | Inst Trans | - | Short Ratio | 11.42 | Perf Half Y | -29.87% |
| Sales | 157.00M | P/B | 1.25 | EPS next Y | -2.74% | ROA | -14.10% | Short Interest | 7.73M | Perf YTD | -15.06% |
| Book/sh | 58.28 | P/C | 3.79 | EPS next 5Y | - | ROE | -16.42% | 52W High | 118.85 -38.83% | Perf Year | 121.71% |
| Cash/sh | 19.18 | P/FCF | - | EPS past 3/5Y | - | ROIC | -15.24% | 52W Low | 29.95 142.74% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 37.95% - | Gross Margin | -14.80% | Volatility | 7.17% 6.13% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 14.89 | EPS Y/Y TTM | 83.68% | Oper. Margin | -348.66% | ATR (14) | 4.30 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.51 | Sales Y/Y TTM | 24.60% | Profit Margin | -253.22% | RSI (14) | 56.83 | Recom | 2.43 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.74 | EPS Q/Q | 26.13% | SMA20 | 3.15% | Beta | 2.61 | Target Price | 65.17 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | 28.13% | SMA50 | 8.54% | Rel Volume | 0.80 | Prev Close | 70.27 |
| Employees | 910 | LT Debt/Eq | 0.03 | Earnings | Aug 05 | SMA200 | -2.07% | Avg Volume | 668.78K | Price | 72.70 |
| IPO Date | Jun 12, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 17.11% 4.16% | Net Debt/EBITDA | 0.05 | Volume | 532,443 | Change | 3.46% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-15-26 | Reiterated | Mizuho | Neutral | $58 → $65 |
| Jun-05-26 | Reiterated | Goldman Sachs | $60 | |
| May-06-26 | Reiterated | Robert W. Baird | $82 → $70 | |
| May-06-26 | Reiterated | Piper Sandler | Neutral | $54 → $56 |
| Apr-10-26 | Initiated | Mizuho | Neutral | $58 |
| Apr-10-26 | Initiated | Piper Sandler | Neutral | $54 |
| Feb-24-26 | Reiterated | Morgan Stanley | Equal Weight | $110 → $60 |
| Feb-20-26 | Reiterated | Robert W. Baird | $113 → $82 | |
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy | $85 → $80 |
| Feb-17-26 | Initiated | Baird | Outperform | $113 |
Latest News
Aug-04-26
Aug-04-2605:03PM
03:08PM
10:09AM
09:33AM
05:35AM
Aug-03-26
Aug-03-2606:46PM
05:43PM
12:00PM
09:36AM
07:15AM
02:56AM
01:44AM
Aug-02-26
Aug-02-2603:35PM
01:40PM
Company
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 157 | 147 | 126 | 93 | 56 | 15 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 179 | 210 | 204 | 189 | 172 | 115 | 0 | 0 | 0 | |
| Gross Profit | -23 | -63 | -78 | -96 | -116 | -100 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 268 | 276 | 368 | 363 | 296 | 234 | 124 | 89 | 64 | |
| Research and Development | 191 | 196 | 322 | 339 | 330 | 460 | 193 | 167 | 223 | |
| Other Operating Expense | 62 | 0 | 1,421 | 718 | 4,700 | 471 | -1 | 0 | 0 | |
| Operating Income | -544 | -534 | -2,189 | -1,515 | -5,443 | -1,265 | -316 | -256 | -287 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 29 | 0 | 27 | 8 | 2 | 0 | 4 | 11 | 12 | |
| Net Income Before Taxes | -517 | -535 | -2,162 | -1,508 | -5,441 | -1,265 | -312 | -245 | -275 | |
| Income Taxes | -120 | -126 | -135 | -42 | -42 | -17 | 0 | 0 | 0 | |
| Consolidated Net Income | -395 | -408 | -2,027 | -1,466 | -5,399 | -1,248 | -312 | -245 | -276 | |
| Net Income From Continuing Operations | -395 | -408 | -2,027 | -1,466 | -5,399 | -1,248 | -312 | -245 | -276 | |
| Net Income | -395 | -408 | -2,027 | -1,466 | -5,399 | -1,248 | -312 | -245 | -276 | |
| EPS (Recurring) | -10.37 | -11.11 | -63.54 | -47.20 | -173.87 | -40.18 | -2.52 | -1.99 | -2.42 | |
| EPS (Basic, Before Extraordinaries) | -10.37 | -11.11 | -63.54 | -47.20 | -173.87 | -40.18 | -2.52 | -1.99 | -2.42 | |
| EPS (Diluted) | -10.37 | -11.11 | -63.54 | -47.20 | -173.87 | -40.18 | -2.52 | -1.99 | -2.42 | |
| EBITDA | -339 | -378 | -610 | -638 | -588 | -1,207 | -309 | -243 | -269 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 18.99 | 21.54 | 4.53 | — | — | — | — | — | — | |
| Gross Margin | -14.65 | -42.86 | -61.90 | -103.23 | -207.14 | -666.67 | — | — | — | |
| Operating Margin | -346.50 | -363.27 | -1,737.30 | -1,629.03 | -9,719.64 | -8,433.33 | — | — | — | |
| Net Margin | -251.59 | -277.55 | -1,608.73 | -1,576.34 | -9,641.07 | -8,320.00 | — | — | — | |
| Shares Outstanding | 41 | 37 | 32 | 31 | 31 | 31 | 124 | 123 | 114 | |
| Market Capitalization | 2,981 | 3,167 | 571 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Partridge Andrew John | Chief Growth Officer | Jun 04 '26 | Sale | 61.08 | 1,491 | 91,070 | 163,738 | Jun 05 |
| Freidin Aaron | Chief Financial Officer | Apr 08 '26 | Sale | 49.92 | 45,806 | 2,286,526 | 260,669 | Apr 09 |
| RAGUSA ROBERT P | Chief Executive Officer | Apr 08 '26 | Sale | 49.92 | 123,502 | 6,164,923 | 518,582 | Apr 09 |
| Ofman Joshua J. | President | Apr 08 '26 | Sale | 49.92 | 61,665 | 3,078,169 | 371,216 | Apr 09 |
| Freidin Aaron | Chief Financial Officer | Mar 09 '26 | Sale | 47.89 | 2,492 | 119,341 | 306,475 | Mar 09 |
| Ofman Joshua J. | President | Mar 09 '26 | Sale | 47.89 | 2,937 | 140,650 | 432,881 | Mar 09 |
| RAGUSA ROBERT P | Chief Executive Officer | Mar 09 '26 | Sale | 47.89 | 7,461 | 357,296 | 642,084 | Mar 09 |
| RAGUSA ROBERT P | Chief Executive Officer | Mar 05 '26 | Sale | 53.01 | 980 | 51,950 | 649,545 | Mar 09 |
| Ofman Joshua J. | President | Mar 05 '26 | Sale | 53.01 | 690 | 36,577 | 435,818 | Mar 09 |
| Freidin Aaron | Chief Financial Officer | Mar 05 '26 | Sale | 53.01 | 655 | 34,722 | 308,967 | Mar 09 |
| Freidin Aaron | Chief Financial Officer | Mar 02 '26 | Sale | 50.17 | 9,573 | 480,244 | 309,622 | Mar 03 |
| Ofman Joshua J. | President | Mar 02 '26 | Sale | 50.16 | 17,002 | 852,848 | 436,508 | Mar 03 |
| RAGUSA ROBERT P | Chief Executive Officer | Mar 02 '26 | Sale | 50.17 | 37,504 | 1,881,417 | 650,525 | Mar 03 |
| RAGUSA ROBERT P | Chief Executive Officer | Dec 03 '25 | Sale | 95.24 | 40,000 | 3,809,535 | 688,029 | Dec 05 |
| Ofman Joshua J. | President | Dec 03 '25 | Sale | 100.00 | 13,000 | 1,300,000 | 368,818 | Dec 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.